Life at 100.4: An Immersive Social Virtual Reality (VR) Education Tool for Adolescent and Young Adult Cancer Patients and Caregivers

NCT07224204 | Recruiting

• 2 other identifiers: 20000407341R41NR022239
• Study Type: interventional
• Target: 45
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to design and Beta test the Life at 100.4, an immersive social virtual reality education tool, with an anticipated 5 patient-caregiver-provider triads.Patients at Yale Pediatric Hematology and Oncology with a new oncologic diagnosis and their caregivers will be eligible for enrollment. Investigators will determine the feasibility and acceptability of implementing Life at 100.4 using validated measures.

Conditions

Cancer; Adolescent Cancer; Young Adult Cancer

Keywords

Adolescent Cancer Patients and Caregivers; Young Adult Cancer Patients and Caregivers

Outcome Measures

Primary Outcomes (3)

• Multimodal Presence Scale for Virtual Environments

  A 15-item validated tool to assess presence in VR. There are five items for each of the three dimensions, Physical Presence, Social Presence, and Self-Presence, scored on a 5-point Likert scale, from 1 (strongly disagree) to 5 (strongly agree). Total score for each dimension 1-5 with higher scores indicating a stronger sense of presence in that dimension.

  immediately post-intervention, up to 2 hours

• System Usability Scale (SUS)

  A 10-item questionnaire with responses provided on a Likert scale. The SUS has been applied in evaluating the usability of different websites, software, and human computer interfaces. The final score is on a scale of 0-100. Higher scores indicate more usability.

  immediately post-intervention, up to 2 hours

• Technology Acceptance Model (TAC)

  Technology Acceptance Model questionnaire with questions related to Perceived Usefulness and Perceived Ease of Use. Total score range 1-5 with higher scores indicating higher acceptance and use.

  immediately post-intervention, up to 2 hours

Study Arms (2)

Objective 1: Focus groups

NO INTERVENTION

Participants will participate in a 45 minute to 1-hour long focus group with similar stake holders to inform the intervention. These groups will take place via Zoom teleconferencing software, have 4-6 participants per group and will be run by appropriately trained study staff.

Objective 3:

EXPERIMENTAL

Beta testing of VR-based educational intervention, Life at 100.4, to improve understanding of fever with neutropenia, how and when to check for it, and what to do when they have a fever.

Behavioral: Life at 100.4

Interventions

Life at 100.4 BEHAVIORAL

An Immersive Social Virtual Reality Education Tool, participation up to 2 hours

Objective 3:

Eligibility Criteria

• Age: 13 Years - 39 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Newly diagnosed with a malignancy or bone marrow failure condition
• Planned to receive chemotherapy and receive a central line

You may not qualify if:

• Medical contraindication to virtual reality including head wounds and history of seizure with flashing lights
• No plan to receive chemotherapy

Sponsors & Collaborators

• The Glimpse Group Inc: collaborator
• Yale University: lead
• National Institute of Nursing Research (NINR): collaborator

Study Sites (1)

Pediatric Hematology/Oncology Clinic in Smilow Cancer Hospital

New Haven, Connecticut, 06520, United States

RECRUITING

MeSH Terms

Conditions

Neoplasms

Study Officials

• Asher Marks, MD

  Yale University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Asher Marks, MD

CONTACT

203-785-4640; asher.marks@yale.edu

Vidya Puthepura, MD

CONTACT

203-785-4640; vidya.puthenpura@yale.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: For Objective 1, an anticipated 20-30 participants for focus groups. For Objective 3, an anticipated 15 participant-caregiver-provider triads. Participants with new oncologic diagnosis and their caregivers at the Yale Pediatric Hematology/Oncology Clinic will be eligible for enrollment.

Study Record Dates

• First Submitted: October 31, 2025
• First Posted: November 4, 2025
• Study Start: February 11, 2026
• Primary Completion (Estimated): April 1, 2027
• Study Completion (Estimated): April 1, 2027
• Last Updated: February 25, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)